Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.

Journal Article (Clinical Trial;Journal Article)

Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.

Full Text

Duke Authors

Cited Authors

  • Tetef, M; Leong, L; Ahn, C; Akman, S; Chow, W; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Doroshow, JH

Published Date

  • 1999

Published In

Volume / Issue

  • 17 / 2

Start / End Page

  • 114 - 117

PubMed ID

  • 10071595

International Standard Serial Number (ISSN)

  • 0735-7907


  • eng

Conference Location

  • England